Page last updated: 2024-12-06
cyclarbamate
Description
Cyclarbamate is a cyclic carbamate derivative that has been investigated for its potential therapeutic effects. It has been shown to possess anxiolytic, anticonvulsant, and muscle relaxant properties. However, its clinical use has been limited due to concerns about its safety and efficacy. Cyclarbamate is typically synthesized through a multi-step process involving the reaction of an appropriate amine with a cyclic carbonate. Its mechanism of action is not fully understood, but it is believed to act on the central nervous system, potentially modulating the activity of neurotransmitters such as GABA. Research on cyclarbamate has been focused on exploring its potential therapeutic applications and understanding its pharmacological profile. Despite its limitations, cyclarbamate remains an intriguing compound that warrants further investigation.'
cyclarbamate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 72076 |
CHEMBL ID | 2104142 |
CHEBI ID | 135553 |
SCHEMBL ID | 547006 |
MeSH ID | M0045760 |
Synonyms (26)
Synonym |
5779-54-4 |
cyclarbamate |
CHEBI:135553 |
[1-(phenylcarbamoyloxymethyl)cyclopentyl]methyl n-phenylcarbamate |
cyclopentaphene |
CHEMBL2104142 |
c-1428 , |
cyclarbamatum [inn-latin] |
cyclarbamatum |
m 906 |
einecs 227-302-7 |
ciclarbamato |
c 1428 |
1,1-cyclopentanedimethanol dicarbanilate |
unii-779291866j |
cyclarbamate [inn:ban:dcf] |
779291866j , |
ciclarbamato [inn-spanish] |
SCHEMBL547006 |
cyclarbamate [mi] |
cyclarbamate [inn] |
cyclarbamat |
DTXSID60206480 |
Q5198119 |
calmalone; camalon; casmalon; cyclopentaphene |
AKOS040751345 |
Drug Classes (1)
Class | Description |
carbamate ester | Any ester of carbamic acid or its N-substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 7 (87.50) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.94
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.94 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.14 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |